Many years ago, I learned that one good way to make money in the market is to understand the consensus view and then figure out where it is most likely to be wrong. Not that the consensus is always wrong – it’s usually right BUT fully priced into the market, writes Michael Murphy, editor of New World Investor.

Apple (AAPL) reported a good March quarter. Revenues fell a less-than-expected 2.5% from last year to $94.84 billion, nicely above the $92.84 billion estimate. Earnings were the same as last year, $1.52, solidly above the $1.43 consensus, notes Michael Murphy, editor of New World Investor.

The S&P 500 bottomed on October 12 at 3491.58. It’s a Wall Street shibboleth that the market leads the economy by six months, so let’s see – November 12, December 12, January 12, February 12, March 12, April 12 – yep, here we are. All the forces behind the Fed’s tightening regime should be peaking. I like Meta Platforms (META) in this environment, explains Michael Murphy, editor of New World Investor.

In the wake of the Silicon Valley Bank et. al. failures, Wall Street sentiment has turned from mere “doom and gloom” to outright “apocalyptic.” Retail investors are also fearful, as they always are when stocks are cheap. That means it’s time to buy another name: Freeport McMoRan (FCX), argues Michael Murphy, Editor of New World Investor.

Small-cap biotech is not affected by the economy and ignored by the institutions and computerized algo traders. You must Be early, be right, and hold on to turn every $1 into $20 over the next few years. Join this session to learn Michael Murphys three early biotech stock picks. Its his job to be right about the science and getting FDA approval. Its your job to hold on until its time to cash in.